Dr. Daniel has contributed to improving healthcare as physician, educator, basic and translational scientist and, most recently, as a senior research and development executive in biotechnology and biopharmaceutical companies.
He is currently Chairman & President of Vividion Therapeutics, is a venture partner at ARCH Venture Partners, and serves as director at Zafgen, Inc., JUNO Therapeutics, Magenta Therapeutics, and VIR Bio. Dr. Daniel is a Trustee of Reed College, advises the Parker Institute for Cancer Research, aTyr Pharma, Inc., is a director of the Alliance for Lupus Research and serves as a member of the Biomedical Science Advisory Board of Vanderbilt University Medical Center. He was recently Chairman of Research at Celgene Corporation, and served as President of Research and Early Development at Celgene over the past decade. Previously, he served as Chief Scientific Officer and Director at Ambrx Inc., was Vice President of Research at Amgen, and Senior Vice President of Discovery Research at Immunex.
A nephrologist and former academic investigator, Dr. Daniel was C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University and co-director of the Vanderbilt Medical Scientist Training Program (MD/PhD Program). He formerly led NIH supported research groups, conducted research in the Howard Hughes Medical Institute, earned his M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital.